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BACKGROUND: Immune perturbation likely affects the development of Kaposi sarcoma (KS) among people infected with the
KS-associated herpesvirus (KSHV). We tested whether KSHV-seropositive individuals or cases of classic KS (cKS), which typically
originates in the leg, had differing delayed-type hypersensitivity (DTH) in the forearm or leg.
METHODS: Mantoux DTH with three antigens (Candida, tetanus, PPD) was performed on the forearm and leg of 15 cKS cases,
14 KSHV-positives without KS, and 15 KSHV-negative controls. The diameters of induration responses were compared by group
and body site.
RESULTS: Leg DTH was greater than forearm DTH among controls (mean difference 5.6mm, P¼0.0004), whereas this was not
observed in cKS cases ( 2.2mm, P¼0.32) or KSHV-positives (0.5mm, P¼0.56). Leg-minus-forearm DTH difference was greater
in controls compared with cKS cases (P¼0.004) and KSHV-positives (P¼0.002). Leg-plus-forearm DTH was similar in controls
(mean 28.2mm) and cKS cases (24.5mm, P¼0.60), but it was reduced in KSHV-positives (11.8mm, P¼0.02), particularly in the leg
(P¼0.004) and marginally in the forearm (P¼0.07).
CONCLUSION: KS cases had weaker DTH only in the leg, whereas both body sites appeared weaker in KSHV-positives without KS.
Both systemic and regional immune alterations may influence the development of this malignancy.
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Kaposi sarcoma (KS) is caused by infection with the KS-associated
herpesvirus (KSHV, also known as human herpesvirus 8), but only
a fraction of infected people develop the disease. The risk of KS
development is markedly increased for people with a severe
perturbation in immunity, especially HIV/AIDS. In contrast, the
risk for classic KS (cKS) is approximately 100-fold lower than for
AIDS KS (Vitale et al, 2001; Engels et al, 2003), and the immune
defect underlying cKS is unknown.
Thirty years ago, delayed-type hypersensitivity (DTH) responses
to dinitrochlorobenzene (DNCB) were noted to be absent in
16 African, non-AIDS KS patients who had very advanced disease
but not in 30 who had limited disease (Master et al, 1970).
Subsequently, two cases of cKS (Ruocco et al, 1984; Ruocco and
Satriano, 1986) and a small series of African, non-AIDS KS cases
(Ziegler and Katongole-Mbidde, 1996) were reported to have
seriously deficient DTH in the leg, where the disease typically
originates. This study tested two hypotheses – first that DTH was
generally low in cKS patients, and then that DTH was specifically
deficient in the organ at highest risk – the skin of the leg.
MATERIALS AND METHODS
Research participants and KSHV serology
From the 2002–2006 population-based cKS case–control study
(Anderson et al, 2008), which ascertained cKS cases and
randomly sampled controls from the entire island of Sicily,
participants for this study were recruited from those who were
alive and who lived not more than 1-h driving time from the clinic
in Palermo. All such cKS cases and KSHV-seropositives were
recruited, as were a random sample of the larger population of
KSHV-seronegative controls. During 2009, they were contacted by
telephone and given a pair of clinic appointments for intradermal
injection of the antigens and measurement of DTH responses 48h
later. As reported in detail (Anderson et al, 2008), seropositive
subjects had antibodies detected by immunofluorescence assay
(IFA) against the KSHV latency-associated nuclear antigen
(LANA) or by enzyme immunoassay (EIA) against the KSHV
K8.1 antigen; seronegative subjects were non-reactive against
KSHV LANA and lytic antigens by IFA and against KSHV K8.1
and ORF73 antigens by EIA. Subjects with indeterminate KSHV
serology (Anderson et al, 2008) were excluded from this
study. The study was approved by institutional review boards at
the University of Palermo and at the National Cancer Institute
in the USA.
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Following informed consent and an examination for cKS lesions,
one dermatologist identified disease-free areas on the volar surface
of the forearm and the medial surface of the thigh. Using
the conventional Mantoux method, six wheals were raised by
intradermal injection of 100ml of each antigen solution (tetanus
toxoid (Imovax Tetano, Sanofi Pasteur MSD S.p.a., Rome, Italy); PPD
(five tuberculin units); and C. albicans (Candin; Allermed Labora-
tories Inc., San Diego, CA, USA)). Each participant was observed for
30min for possible acute reactions, of which there were none.
Approximately 48h after administration, the same dermato-
logist examined each injection site on the forearm and leg. The
perpendicular diameters of palpable induration were determined
using the ball-point pen method (Sokal, 1975), measured with
calipers, and tabulated. Induration with a minimum diameter
X5mm was categorised as positive, else negative. Cross-sectional
area (the product of the perpendicular diameters) was calculated
for indurations with minimum diameter X2mm.
Total lymphocyte counts and CD4 and CD8 T-cell subsets were
determined by the HIV/AIDS clinical monitoring laboratory using
standard cytometric methods.
Analysis plan and methods
We compared three groups – cKS cases, KSHV-seropositives, and
KSHV-seronegative controls (Anderson et al, 2008) – on DTH in
the forearm; DTH in the leg; difference in DTH between the
forearm and leg (a standardised measure of the leg); and finally
sum of DTH in the forearm-plus-leg (a more general measure).
The primary measure was the product of the perpendicular
diameters of induration areas, which were transformed with the
square root function (mean diameter) to better approximate
normal distributions. Mean square-root values were transformed
back to the original scale for presentation. Within-subject
differences in mean induration diameters in the forearm and leg
were compared with Student’s t-test, either paired (within subject)
or unpaired (between groups), and with analysis of variance.
Categorical data (positive–negative responses) were compared
with appropriate tests (Kruskal and Wallis, 1952; Armitage, 1971),
but these are not presented because the associations were very
similar to those with continuous (mean diameter) responses.
Differences in lymphocyte and T-cell subsets were tested with one-
way analysis of variance. Mean and standard distribution (s.d.) of
induration diameter and cell counts by number of KS lesions in
the cases are presented. Two-sided P-values p0.05 were deemed to
be statistically significant.
RESULTS
We evaluated 44 participants, of whom 9 were female. The three
groups did not differ with respect to age (P¼0.48, mean 66 years).
They included 35 residents of the province of Palermo, and
9 residents of the neighbouring provinces of Trapani or Agrigento.
As we reported previously (Anderson et al, 2008), diabetes was
more common in cases (40%) compared with KSHV-seropositives
(zero, P¼0.02) but not compared with seronegative controls (20%,
P¼0.43). Kaposi sarcoma originated on the foot or leg in all
15 cases except 1; a second case developed metastatic KS on the
arm. Nine cases currently had no KS lesions, three had 1–2 lesions,
and three had approximately 20 lesions. Delayed-type hypersensi-
tivity was performed on skin sites (volar forearm and medial
thigh) that were far from KS lesions. The mean diameter of DTH
responses in the forearm and leg of each participant is presented in
Supplementary Table S1. Delayed-type hypersensitivity responses
did not appear to differ by antibody response against KSHV LANA
vs K8.1, but the serology was highly concordant. Specifically, nine
of the KSHV-seropositives had antibodies against LANA, and all
but one had antibodies against K8.1. All cKS cases had antibodies
against K8.1, and all but two had antibodies against LANA. As we
were interested in cumulative DTH, diameters were summed
for each participant, separately in forearm and leg, and then with
the two body sites combined.
First, we compared mean induration in the forearm vs mean
induration in the leg, within each group (Supplementary Table S2).
As shown in Figure 1 (black dashed lines in body images),
the controls had significantly larger responses in the leg than the
forearm (16.9 vs 11.3mm, P¼0.0004). In contrast, leg and forearm
did not differ significantly in the KSHV-positives (P¼0.56) or cKS
cases (P¼0.32) groups.
Second, we performed pair-wise comparisons of the three groups
for size of responses in the forearm, then in the leg (Supplementary
Table S2). As shown in Figure 1 (blue solid lines between body
images), responses in the forearm were marginally smaller in
KSHV-positives (mean 5.7mm) than in controls (11.3mm, P¼0.07)
and cKS cases (13.4mm, P¼0.05), whereas the latter two groups
did not differ from each other (P¼0.58). In the leg, controls had
significantly larger responses in the leg (16.9mm) compared with
KHSV-positives (6.2mm, P¼0.004) but not compared with cKS
cases (11.2mm, P¼0.11). Response sizes in the leg did not differ
between cKS cases and KSHV-positives (P¼0.17).
Within individuals, difference in response sizes by body site was
significantly greater in controls (leg-minus-forearm, 5.6mm)
compared with KSHV-positives (0.5mm, P¼0.002) and cKS cases
( 2.2mm, P¼0.004, Figure 1, lower panel). The three groups
varied significantly from each other in leg-minus-forearm
differences (P¼0.002), and this remained significant after
Controls
Classic KS cases
KSHV-
positives
P =0.0004
P =0.56
P =0.32
P =0.11
P =0.58
P =0.07
P =0.05
P =0.17
P =0.004
Controls
vs KSHV+
Controls vs
cKS cases
KSHV+ vs
cKS cases
Leg-minus-forearm
Leg-plus-forearm
P =0.25
P =0.08
P =0.004
P =0.60
P =0.002
P =0.02
Figure 1 Comparisons of DTH responses within (black dashed lines)
and between (blue solid lines) cases of classic KS, KSHV-seropositive
people without KS, and KSHV-seronegative controls. Upper panel
(body images), blue circles are proportional to the mean responses in
the forearm and leg. Lower panel (table), comparisons of differences
(leg-minus-forearm) and sums (leg-plus-forearm) in responses.
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for 15 comparisons (Figure 1), leg-minus-forearm differences were
marginally significant (P¼0.03–0.06).
The sum of responses (leg-plus-forearm) within individuals was
significantly lower in KSHV-positives (11.8mm) compared with
controls (28.2mm, P¼0.02) and marginally compared with cKS
cases (24.5mm, P¼0.08), whereas the latter two groups did not differ
from each other (Figure 1, lower panel). The three groups varied
significantly from each other in leg-plus-forearm DTH (P¼0.05), and
this remained significant after adjustment for diabetes (P¼0.05).
There were no differences between or across the groups in total
lymphocyte counts, CD4 count or percent, CD8 count or percent,
or CD4/CD8 ratio (PX0.20, Supplementary Table S2). The cKS
cases with 42 lesions tended to have lower CD8 counts (N¼3,
mean 381±345) than cases with fewer lesions (N¼3, 573±173) or
no lesions (N¼9, 543±449). Cases with 42 lesions also tended
to have smaller induration (7.8±3.2mm in forearm, 5.3±4.6mm
in leg) compared with cases with fewer lesions (22.0±5.4mm
in forearm, 17.0±10.5mm in leg) or no lesions (12.3±13.9mm in
forearm, 11.2±10.5mm in leg).
DISCUSSION
We sought to identify whether there were differences in DTH,
overall or between forearm and leg, which were associated with
cKS or with KSHV-seropositivity without KS. We found a large and
highly significant difference between the legs and forearms, with
stronger responses in the legs of controls. In addition, the KSHV-
seropositives had weaker overall responses (arm-plus-leg), includ-
ing significantly weaker responses in the forearm compared with
the cKS cases. These surprising results suggest that cKS cases and
seropositives have divergent DTH responses that may relate to the
development of KS vs remaining KS free.
As our controls have little or no risk of cKS, they represent the
basal condition and thereby approximate DTH in this elderly, general
population. Compared with these controls, the markedly smaller
indurations in the legs of cKS cases support anecdotal reports of
fewer and smaller DTH responses in the leg or foot compared with
the arm (Ruocco et al, 1984; Ruocco and Satriano, 1986; Ziegler and
Katongole-Mbidde, 1996). In contrast, DTH responses in the arm
against DNCB were observed in all of 30 Ugandan patients who had
relatively indolent KS (Master et al, 1970). Our cKS cases and
controls had equivalent responses in the forearm, supporting the
hypothesis that the KS-associated defect in DTH is specifically in the
leg, where classic and endemic KS most often originates.
Stronger DTH in the leg of cKS cases compared with
seropositives is the opposite of what we anticipated. It suggests
that seropositives may be a special and highly informative group.
They have survived with KSHV infection without developing KS,
generally for several decades. (Whitby et al, 2000; Pelser et al,
2009) The observation that the KSHV-seropositives had smaller
indurations (Figure 1), including the arm, raises the hypothesis
that generalised hypo-responsiveness may have reduced their risk
for developing KS. This may appear paradoxical, as HIV infection
causes a profound deficiency of DTH but an enormous increase in
KS risk (Birx et al, 1993; Vitale et al, 2001; Engels et al, 2003).
However, people with HIV also have markedly activated immunity.
In fact, elevated serum level of b2-microglobulin or especially
neopterin is more predictive of AIDS KS than is low CD4
lymphocyte count (Rabkin et al, 1990; Kra ¨mer et al, 1992), and
cKS cases tend to have elevated levels of serum neopterin and
b2-microglobulin (Touloumi et al, 1999; Brown et al, 2006). More-
over, transplant-associated KS was increased with HLA-
mismatched allografts (Mbulaiteye and Engels, 2006), which points
more to immune activation than suppression. In this study,
lymphocyte and T-cell subset levels were not related to KSHV
status, nor did they differ among cKS cases as a whole.
Detection of KSHV viremia is the strongest marker of KS risk
yet identified (Whitby et al, 1995; Engels et al, 2003). Unfortu-
nately, how KSHV-specific immune responses relate to KSHV
viremia, to KS incidence, and even to KS progression or regression
have not been clearly defined (Flores and Goedert, 2010). It would
be of considerable interest to know whether DTH responses
are associated with KSHV viremia in KSHV-seropositive adults.
On the basis of the strong association between viremia and KS
risk, our current data would suggest that viremia should be
associated with stronger DTH responses, perhaps more in the arm
than the leg.
Our study was significantly limited by its small size, which
reflects the rarity of cKS, the relatively low prevalence of people
without KS who have unambiguous KSHV-seropositivity (Ander-
son et al, 2008) and the rigors of performing and reading DTH
responses in a very elderly population. Nonetheless, except for a
paucity of female cKS cases, our groups were well balanced by sex
and age, and these participants are likely to be representative of the
ambulatory general population (Anderson et al, 2008). We did not
evaluate DTH responses in the distal leg, where cKS lesions arise
most often. We purposely did not test the distal leg or foot in cKS
cases to assure that the injections were distant from lesions.
However, these comparisons would be of interest, and probably
valid, in KSHV-seropositives and in cKS cases who have no lesions
near the DTH test site. Finally, with our retrospective case–control
design, reverse causality could account for the observed associa-
tions, with cKS or KSHV-seropositivity leading to differences in
DTH. We observed suggestive differences by number of KS lesions
in our cases, which resemble the heterogeneity by stage of KS
noted previously in Uganda (Master et al, 1970).
In summary, we confirmed that KS cases have diminished
DTH responses in the leg, and we also found evidence, albeit
weaker, for diminished responses in the arm-plus-leg of elderly
KSHV-seropositives who have not developed KS. As we performed
several comparisons, these findings might have emerged merely
by chance. However, they support the hypothesis that KS, in the
absence of HIV infection, is related to intrinsic differences in
immune responses, perhaps in the distal extremities even more so
than systemically.
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